Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication

Blood

Volumn 109, Issue 5, 2007, Pages 1850-1856

  Pilotti, Elisabetta ^a   Elviri, Lisa ^a   Vicenzi, Elisa ^b   Bertazzoni, Umberto ^c   Re, Maria Carla ^d   Allibardi, Sonia ^e   Poli, Guido ^b,f   Casoli, Claudio ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Biotechnology Division Molecular Biology   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROTEIN CCL3L1; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IN VITRO STUDY; LEUKOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION;

EID: 33847348996     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-036046     Document Type: Article

References (36)

1. Venkatesan S, Petrovic A, Van Ryk DI, Locati M, Weissman D, Murphy PM. Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration. J Biol Chem. 2002;277:2287-2301.
2. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 2001;135:782-795.
3. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev. 2002;13:455-481.
4. Modi WS. CCL3L1 and CCL4L1 chemokine genes are located in a segmental duplication at chromosome 17q12. Genomics. 2004;83:735-738.
5. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005;307:1434-1440.
6. Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med. 2001;345:715-724.
7. Grivel JC, Ito Y, Faga G, Santoro F, et al. Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat Med. 2001;7:1232-1235.
8. Casoli C, Vicenzi E, Cimarelli A, et al. HTLV-II down-regulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfected individuals through expression of MIP-1alpha. Blood. 2000;95:2760-2769.
9. Stapleton JT. GB virus type C/Hepatitis G virus. Semin Liver Dis. 2003;23:137-148.
10. Pinto LA, Blazevic V, Patterson BK, Mac Trubey C, Dolan MJ, Shearer GM. Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation. J Virol. 2000;74:4505-4511.
11. Turci M, Pilotti E, Ronzi P, et al. Coinfection with HIV-1 and human T-cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. J Acquir Immune Defic Syndr. 2006;41:100-106.
12. Lewis MJ, Gautier VW, Wang XP, Kaplan MH, Hall WW. Spontaneous production of C-C chemokines by individuals infected with human T lymphotropic virus type II (HTLV-II) alone and HTLV-II/HIV-1 coinfected individuals. J Immunol. 2000;165:4127-4132.
13. Zamarchi R, Indraccolo S, Minuzzo S, et al. Frequency of a mutated CCR-5 allele (delta32) among Italian healthy donors and individuals at risk of parenteral HIV infection. AIDS Res Hum Retroviruses. 1999;15:337-344.
14. Salemi M, Cattaneo E, Casoli C, Bertazzoni U. Identification of IIa and IIb molecular subtypes of human T-cell lymphotropic virus type II among Italian injecting drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:516-520.
15. Gibellini D, Vitone F, Gori E, La Placa M, Re MC. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) viral load by SYBR green real-time RT-PCR technique in HIV-1 seropositive patients. J Virol Methods. 2004;115:183-189.
16. Townson JR, Barcellos LF, Nibbs RJ. Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol. 2002;32:3016-3026.
17. Proost P, Wuyts A, Conings R, Lenaerts JP, Put W, Van Damme J. Purification and identification of natural chemokines. Methods. 1996;10:82-92.
18. Aquaro S, Menten P, Struyf S, et al. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages. J Virol. 2001;75:4402-4406.
19. Brown DA, Nelson FB, Reinherz EL, Diamond DJ. The human interferon-gamma gene contains an inducible promoter that can be transactivated by tax I and II. Eur J Immunol. 1991;21:1879-1885.
20. Dezzutti CS, Sasso DR, Rudolph DL, Lal RB. Down-regulation of interleukin-10 expression and production is associated with spontaneous proliferation by lymphocytes from human T lymphotropic virus type II-infected persons. J Infect Dis. 1998;177:1489-1496.
21. Bovolenta C, Pilotti E, Mauri M, et al. Retroviral interference on STAT activation in individuals coinfected with human T cell leukemia virus type 2 and HIV-1. J Immunol. 2002;169:4443-4449.
22. Bovolenta C, Pilotti E, Mauri M, et al. Human T-cell leukemia virus type 2 induces survival and proliferation of CD34(+) TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-gamma and granulocyte macrophagecolony-stimulating factor. Blood. 2002;99:224-231.
23. Alfano M, Poli G. The cytokine network in HIV infection. Curr Mol Med. 2002;2:677-689.
24. Hirashima M, Ono T, Nakao M, et al. Nucleotide sequence of the third cytokine LD78 gene and mapping of all three LD78 gene loci to human chromosome 17. DNA Seq. 1992;3:203-212.
25. Choe W, Volsky DJ, Potash MJ. Induction of rapid and extensive beta-chemokine synthesis in macrophages by human immunodeficiency virus type 1 and gp120, independently of their coreceptor phenotype. J Virol. 2001;75:10738-10745.
26. Kinter A, Arthos J, Cicala C, Fauci AS. Chemokines, cytokines and HIV: a complex network of interactions that influence HIV pathogenesis. Immunol Rev. 2000;177:88-98.
27. Losana G, Bovolenta C, Rigamonti L, et al. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes. J Leukoc Biol. 2002;72:735-742
28. Creery D, Weiss W, Lim WT, Aziz Z, Angel JB, Kumar A. Down-regulation of CXCR-4 and CCR-5 expression by interferon-gamma is associated with inhibition of chemotaxis and human immunodeficiency virus (HIV) replication but not HIV entry into human monocytes. Clin Exp Immunol. 2004;137:156-165.
29. Miyatake S, Seiki M, Yoshida M, Arai K. T-cell activation signals and human T-cell leukemia virus type I-encoded p40x protein activate the mouse granulocyte-macrophage colony-stimulating factor gene through a common DNA element. Mol Cell Biol. 1988;8:5581-5587.
30. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 1998;8:275-283.
31. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today. 1994;15:575-581.
32. Lehner T, Wang Y, Cranage M, et al. Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates. Immunology. 2000;99:569-577.
33. Bogers WM, Bergmeier LA, Ma J, et al. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. AIDS. 2004;18:25-36.
34. Xiang J, Wunschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med. 2001;345:707-714.
35. Xiang J, George SL, Wunschmann S, Chang Q, Klinzman D, Stapleton JT. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet. 2004;363:2040-2046.
36. Bronke C, Westerlaken GH, Miedema F, Tesselaar K, van Baarle D. Progression to CMV end-organ disease in HIV-1-infected individuals despite abundance of highly differentiated CMV-specific CD8+ T-cells. Immunol Lett. 2005;97:215-224.